首页> 美国卫生研究院文献>Frontiers in Neurology >Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features Treatments Influencing Factors and Outcomes
【2h】

Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features Treatments Influencing Factors and Outcomes

机译:华南中部儿童髓鞘少突胶质糖蛋白(MOG)抗体疾病:临床特征治疗影响因素和结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background and purpose: The clinical and radiological features of myelin oligodendrocyte glycoprotein antibody (MOG-Ab) diseases vary among the patients and studies. In addition, the clinical significance of MOG-Ab for the diagnosis, treatment, and prognosis is not yet established. Therefore, we aimed to evaluate the clinical, radiological, treatments and outcome features of MOG-Ab diseases in Central Southern part of China.>Methods: A retrospective study of children with MOG-Ab disease was carried out from January 2015 to October 2018. Demographics, clinical features, treatments, and outcomes were reviewed. Some of the clinical information was compared including the annualized relapse rates (ARRs) before and after treatment with disease-modifying drugs (DMDs).>Results: Twenty-five patients with MOG-Ab disease were recruited. The onset age ranged from 3 to 12.4 years old. 13 were females and 12 were males. The median follow-up period was 15 months (range 7–63). Most of the cases that aged ≤9 years presented with fever (47.4%), encephalopathy (47.4%), and lesions on white matter and/or deep gray matter (52.6%). While most of those aged above 9 years presented with optic neuritis (ON) (66.7%), and lesions on spinal cord and/or optic nerve (50%). Until the last follow-up, 10 (40%) cases had multiphasic courses while 15 (60%) had a monophasic course, and the mean follow-up time was statistically significant (10.67 vs. 31 months, p = 0.0001). DMDs such as rituximab (RTX) or/and azathioprine (AZP) or mycophenolate mofetil (MMF) were used at least once in 56% of the cases. The ARR before and after treatment was 2.4 and 0 respectively (p < 0.05). The median Expanded Disability Status Scale scores of our study were 0 (range 0–2). 96% (24/25) of the cases had a full recovery.>Conclusions: MOG-Ab disease among Chinese children share the same clinical characteristics with Caucasians. However, the Chinese children seem to have a better prognosis than Caucasians. There is an age-dependent phenotypes, as brain involvement is more frequently seen in children younger or equal to 9 years while ON and neuromyelitis optica spectrum disorders are commonly seen in children older than 9 years. DMDs, such as AZA, MMF or RTX, can reduce the ARR.
机译:>背景和目的:髓磷脂少突胶质细胞糖蛋白抗体(MOG-Ab)疾病的临床和放射学特征因患者和研究而异。此外,尚未确定MOG-Ab在诊断,治疗和预后方面的临床意义。因此,我们旨在评估中国中南部MOG-Ab疾病的临床,放射学,治疗方法和结局特征。>方法:回顾了2015年1月至2018年10月的人口统计学,临床特征,治疗方法和结局。比较了一些临床信息,包括疾病改变药物(DMD)治疗前后的年复发率(ARR)。>结果:招募了25例MOG-Ab病患者。发病年龄为3至12.4岁。 13位为女性,12位为男性。中位随访期为15个月(范围7-63)。 ≤9岁的大多数病例表现为发烧(47.4%),脑病(47.4%)以及白质和/或深灰质病变(52.6%)。而大多数9岁以上的人表现为视神经炎(ON)(66.7%),以及脊髓和/或视神经病变(50%)。直到最后一次随访,有10例(40%)患者具有多相病程,而15例(60%)具有单相病程,平均随访时间具有统计学意义(10.67 vs. 31个月,p = 0.0001)。在56%的病例中,至少使用了一次rituximab(RTX)或/和硫唑嘌呤(AZP)或霉酚酸酯(MMF)等DMD。治疗前后的ARR分别为2.4和0(p <0.05)。我们研究的扩展残疾状况量表中位数为0(范围为0–2)。 96%(24/25)的病例完全康复。>结论:中国儿童中的MOG-Ab疾病与白种人具有相同的临床特征。但是,中国孩子的预后似乎比白种人好。存在年龄依赖性的表型,因为在9岁以下或9岁以下的儿童中脑部受累更为常见,而在9岁以上的儿童中通常可见到ON和视神经脊髓炎谱系障碍。 DZA(例如AZA,MMF或RTX)可以降低ARR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号